Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

RDHL

Redhill Biopharma (RDHL)

Redhill Biopharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RDHL
DateTimeSourceHeadlineSymbolCompany
25/02/202523:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
25/02/202523:00PR Newswire (US)RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus RoyaltiesNASDAQ:RDHLRedhill Biopharma Ltd
04/02/202523:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
04/02/202523:00PR Newswire (US)RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerNASDAQ:RDHLRedhill Biopharma Ltd
04/02/202508:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
04/02/202508:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RDHLRedhill Biopharma Ltd
21/01/202523:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
21/01/202523:00PR Newswire (US)RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing PublishedNASDAQ:RDHLRedhill Biopharma Ltd
10/12/202423:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
10/12/202423:00PR Newswire (US)Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentNASDAQ:RDHLRedhill Biopharma Ltd
02/12/202423:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
02/12/202423:00PR Newswire (US)RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtNASDAQ:RDHLRedhill Biopharma Ltd
15/11/202404:22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RDHLRedhill Biopharma Ltd
28/10/202422:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
28/10/202422:00PR Newswire (US)RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDNASDAQ:RDHLRedhill Biopharma Ltd
22/10/202422:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
22/10/202422:00PR Newswire (US)RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryNASDAQ:RDHLRedhill Biopharma Ltd
15/10/202421:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
14/10/202422:00PR Newswire (US)RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentNASDAQ:RDHLRedhill Biopharma Ltd
01/10/202421:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
01/10/202421:00PR Newswire (US)RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansNASDAQ:RDHLRedhill Biopharma Ltd
30/09/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
30/09/202421:00PR Newswire (US)RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041NASDAQ:RDHLRedhill Biopharma Ltd
18/09/202423:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
17/09/202423:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
09/09/202421:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
09/09/202421:00PR Newswire (US)RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology GuidelinesNASDAQ:RDHLRedhill Biopharma Ltd
05/09/202422:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
05/09/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
05/09/202421:00PR Newswire (US)RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:RDHLRedhill Biopharma Ltd
 Showing the most relevant articles for your search:NASDAQ:RDHL